Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 2/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10565256 | 0.90 | MEN1 (0.59) | SHBGESR1ESR2MEN1KMT2A | |
| SCHEMBL10563938 | 0.87 | PIK3CA (0.77) | SHBGESR1ESR2MEN1KMT2A | |
| SCHEMBL6245947 | 0.87 | MEN1 (0.68) | SHBGESR2MEN1KMT2AMAPT | |
| SCHEMBL27700015 | 0.86 | PIK3CA (0.74) | SHBGESR1ESR2MEN1KMT2A | |
| SCHEMBL10076768 | 0.86 | MEN1 (0.55) | SHBGESR1ESR2MEN1KMT2A | |
| SCHEMBL5268587 | 0.84 | SMN1; SMN2 (0.63) | SHBGMEN1KMT2AMAPTPIK3CA | |
| SCHEMBL10560823 | 0.82 | MAPT (0.55) | SHBGMEN1KMT2AMAPTPIK3CA | |
| SCHEMBL133679 | 0.80 | ESR1 (0.60) | SHBGESR1ESR2MEN1KMT2A | |
| SCHEMBL6847306 | 0.80 | PIK3CA (0.82) | SHBGESR1ESR2MEN1KMT2A | |
| SCHEMBL8703963 | 0.79 | PIK3CA (0.70) | SHBGESR1ESR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-10-06 | — | — | US | disclosed |
| US-9381186-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-12-10 | — | — | US | disclosed |
| US-9138478-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2407462-B1 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS INC (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2407462-B1 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MEI PHARMA, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8697891-B2 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2407462-A1 | Substituted chroman derivatives, medicaments and use in therapy | Marshall Edwards, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-1794141-B1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS INC (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-1794141-B1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS INC (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-12-24 | — | — | US | disclosed |
| US-7601855-B2 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD (AU) | 2009-10-13 | — | — | US | disclosed |
| US-7601855-B2 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD (AU) | 2009-10-13 | — | — | US | disclosed |
| US-7601855-B2 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD (AU) | 2009-10-13 | — | — | US | disclosed |
| EP-1794141-A4 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RES PTY LTD (AU) | 2009-05-27 | — | — | EP | disclosed |
| EP-1794141-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | Novogen Research Pty. Ltd. (AU) | 2007-06-13 | — | — | EP | disclosed |
| US-20060074127-A1 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD | 2006-04-06 | — | — | US | disclosed |
| WO-2006032085-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | SHBG 2850/4885ESR1 1328/4885ESR2 1134/4885 |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | SHBG 2850/4885ESR1 1328/4885ESR2 1134/4885 |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | SHBG 2850/4885ESR1 1328/4885ESR2 1134/4885 |
| US-20060074127-A1 | anticancer agents; chemotherapeutic selective agents | MCL1, TOP2A, TP53 | SHBG 4182/4885ESR1 3900/4885ESR2 2921/4885 |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | SHBG 2850/4885ESR1 1328/4885ESR2 1134/4885 |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | SHBG 2850/4885ESR1 1328/4885ESR2 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.